Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prev close 41.06 · gapped above the open, then crossed back over prior close. High/low 41.49 at 4:00 am ET, 40.63 at 11:00 am ET.
Each disclosed tie as a share of both companies’ annual revenue. The bigger share is the side that would feel it if the relationship ended.
| Partner | % of their revenue | % of SUPN revenue | Skew |
|---|---|---|---|
| CAHCardinal Health, Inc. | 0.06% | 20.00% | 354× |
| CNCCencora, Inc. | 0.07% | 20.00% | 271× |
| MCKMcKesson Corporation | 0.04% | 20.00% | 561× |
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“Each of our three major customers, Cencora, Inc., Cardinal Health, Inc., and McKesson Corporation, individually accounted for more than 20% of our total product revenue in 2024 and collectively accounted for more than 77% of our total product revenue in 2024.”
$144M relationship354× more of SUPN’s book than CAH’s
basisSUPN fy2025 · closed 2025-12 $719MCAH fy2026 · closed 2026-06 $254B
The two fiscal years close in different months, so the derived share compares periods that do not line up exactly.
FILING10-K0001356576-25-000017cik 0001356576
“Each of our three major customers, Cencora, Inc., Cardinal Health, Inc., and McKesson Corporation, individually accounted for more than 20% of our total product revenue in 2024 and collectively accounted for more than 77% of our total product revenue in 2024.”
$144M relationship271× more of SUPN’s book than CNC’s
basisSUPN fy2025 · closed 2025-12 $719MCNC fy2025 · closed 2025-12 $195B
FILING10-K0001356576-25-000017cik 0001356576
“Each of our three major customers, Cencora, Inc., Cardinal Health, Inc., and McKesson Corporation, individually accounted for more than 20% of our total product revenue in 2024 and collectively accounted for more than 77% of our total product revenue in 2024.”
$144M relationship561× more of SUPN’s book than MCK’s
basisSUPN fy2025 · closed 2025-12 $719MMCK fy2026 · closed 2026-03 $403B
The two fiscal years close in different months, so the derived share compares periods that do not line up exactly.
FILING10-K0001356576-25-000017cik 0001356576
“Adamas Operations, LLC (Adamas Operations), a wholly-owned indirect subsidiary of Supernus Pharmaceuticals, Inc., wholly owns the patents and patent applications related to GOCOVRI and Osmolex ER and has a license agreement with Supernus Pharmaceuticals, Inc., granting Supernus Pharmaceuticals, Inc. rights to market and sell GOCOVRI.”
FILING10-K0001356576-26-000011cik 0001356576
“Per the Agreement, Britannia has an obligation to supply us with APOKYN for our marketing and sale of the product.”
FILING10-K0001356576-25-000017cik 0001356576
“Sage Therapeutics, LLC, a wholly-owned indirect subsidiary of Supernus Pharmaceuticals, Inc., has granted Supernus Pharmaceuticals, Inc. a license to market and sell zuranolone in the United States.”
FILING10-K0001356576-26-000011cik 0001356576
“We have a license agreement with United Therapeutics Corporation to use one of our proprietary technologies in an oral formulation of treprostinil diethanolamine, or treprostinil, for the treatment of pulmonary arterial hypertension and for other indications.”
FILING10-K0001356576-25-000017cik 0001356576
“In October 2021, we entered into an amendment to the Merz Agreement which increased the price of the annual purchase commitment of MYOBLOC from €3.0 million to approximately €3.9 million.”
FILING10-K0001356576-25-000017cik 0001356576
“For example, MDD US Operations, LLC, a wholly-owned indirect subsidiary of Supernus Pharmaceuticals, Inc., is the exclusive licensee and distributor of APOKYN and ONAPGO in the United States and its territories.”
FILING10-K0001356576-25-000017cik 0001356576
“Royalty, licensing and other revenues increased by $15.3 million from $24.1 million in 2024 to $39.4 million in 2025, primarily due to an increase in licensing revenues related to the achievement of a regulatory milestone under our collaboration agreement with Shionogi.”
FILING10-K0001356576-26-000011cik 0001356576
“We have obligations from the Development Agreement with Navitor Inc. we entered into in April 2020.”
FILING10-K0001356576-25-000017cik 0001356576
“While Biogen is obligated to reimburse us for the costs of supply related to marketing and sales in the Biogen Territory, we are required to fund the initial cash payments to third-party contract manufacturing organizations prior to receiving reimbursement from Biogen.”
FILING10-K0001356576-26-000011cik 0001356576
Watchlist prices, news filtered to it, and its next report on your desk.
Supernus Pharmaceuticals, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
Supernus Pharmaceuticals, Inc. has 5 disclosed suppliers and 7 disclosed customers. Each one is named in an SEC filing, either Supernus Pharmaceuticals, Inc.’s own annual report or the counterparty’s, and carries the sentence that discloses it.
SUPN (Supernus Pharmaceuticals, Inc.) has 5 disclosed suppliers and 7 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: CNC −2.06%, in healthcare.